Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825

BACKGROUND: We sought to identify clinical and genetic predictors of temozolomide-related myelotoxicity among patients receiving therapy for glioblastoma. METHODS: Patients (n = 591) receiving therapy on NRG Oncology/RTOG 0825 were included in the analysis. Cases were patients with severe myelotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheurer, Michael E, Zhou, Renke, Gilbert, Mark R, Bondy, Melissa L, Sulman, Erik P, Yuan, Ying, Liu, Yanhong, Vera, Elizabeth, Wendland, Merideth M, Youssef, Emad F, Stieber, Volker W, Komaki, Ritsuko R, Flickinger, John C, Kenyon, Lawrence C, Robins, H Ian, Hunter, Grant K, Crocker, Ian R, Chao, Samuel T, Pugh, Stephanie L, Armstrong, Terri S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587696/
https://www.ncbi.nlm.nih.gov/pubmed/36299794
http://dx.doi.org/10.1093/noajnl/vdac152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587696/
https://www.ncbi.nlm.nih.gov/pubmed/36299794
http://dx.doi.org/10.1093/noajnl/vdac152

Ejemplares similares